摘要
目的探讨阿托伐他汀对H型高血压患者血浆同型半胱氨酸（Hcy）及颈动脉粥样硬化程度的影响。方法入选50~79岁H型高血压伴颈动脉硬化患者180例,随机分为治疗组（n=92）及对照组（n=88）,治疗组在常规降压基础上加用阿托伐他汀每天20 mg,对照组给予常规降压治疗。治疗6个月,观察两组研究对象治疗前后血压、血脂、Hcy、高敏C反应蛋白、颈动脉内膜中膜厚度的变化。结果治疗6个月后,治疗组低密度脂蛋白胆固醇从治疗前的2.69±0.44 mmol/L降至1.95±0.37 mmol/L,Hcy从治疗前的15.86±3.37μmol/L降至9.96±3.35μmol/L,高敏C反应蛋白从治疗前的5.88±2.82 mg/L降至3.75±2.37 mg/L,颈动脉内膜中膜厚度从治疗前的1.97±0.76 mm降至1.47±0.68 mm（均P〈0.05）。对照组治疗前后上述指标无明显变化。结论对于H型高血压患者,在常规降压基础上加用阿托伐他汀能明显降低血浆同型半胱氨酸水平,抑制炎症反应,减缓动脉粥样硬化斑块的形成。
Aim To investigate the effects of atorvastatin calcium on plasma homocysteine（ Hcy） and carotid artery atherosclerosis in patients with H type hypertension. Methods 180 cases of H type hypertensive patients（ 50 ~79 years old） were randomly divided into atorvastatin（ 10 mg / d） treatment group（ n = 92） and conventional treatment group i. e. control group（ n = 88）. Blood pressure,blood lipids,Hcy,high-sensitive C-reactive protein（ hs-CRP）,and intima-media thickness（ IMT） were determined before and after 6 months treatment in all patients. Results In atorvastatin treatment group,after 6 months treatment,the level of low density lipoprotein cholesterol was significantly decreased from 2. 69 ± 0. 44 mmol / L to 1. 95 ± 0. 37 mmol / L; the level of Hcy was significantly decreased from 15. 86 ± 3. 37 μmol /L to 9. 96 ± 3. 35 μmol / L; the level of hs-CRP was significantly decreased from 5. 88 ± 2. 82 mg / L to 3. 75 ± 2. 37 mg / L;the IMT was significantly decreased from 1. 97 ± 0. 76 mm to 1. 47 ± 0. 68 mm（ all P〈0. 05）. No significant change was observed in control group. Conclusion On the basis of conventional antihypertension,atorvastatin can significantly decrease the level of plasma Hcy,inhibit inflammatory reaction,and slow down the formation of atherosclerotic plaque in patients with H type hypertension.
出处
《中国动脉硬化杂志》
CAS
北大核心
2015年第8期817-820,共4页
Chinese Journal of Arteriosclerosis
